# Safety of Lopinavir/Ritonavir (Kaletra) in HIV/HCV Co-infected Subjects vs Baseline Liver Biopsy Metavir Score

> **NCT00234975** · PHASE4 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 86 (actual)

## Conditions studied

- HIV Infection

## Interventions

- **DRUG:** Lopinavir/Ritonavir

## Key facts

- **NCT ID:** NCT00234975
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2013-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00234975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00234975, "Safety of Lopinavir/Ritonavir (Kaletra) in HIV/HCV Co-infected Subjects vs Baseline Liver Biopsy Metavir Score". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00234975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*